COVID-19 Pharmacovigilance Flexibilities 'Must Remain' In Non-EU Markets
Companies Are Concerned Positive Changes May Be Rolled Back After Pandemic Ends
Executive Summary
An EU industry group is scrutinizing the several ‘impactful’ changes made by countries to their pharmacovigilance processes amid the ongoing COVID-19 pandemic. The group is hoping these changes can help its ongoing efforts to create ‘right size’ systems where there is a need to further develop infrastructure for pharmacovigilance.